LAE-001 is under clinical development by Laekna Therapeutics Shanghai and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect LAE-001’s likelihood of approval (LoA) and phase transition for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer took place on 12 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their LAE-001 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

LAE-001 overview

LAE-001 is under development for the treatment of metastatic castration-resistant prostate cancer. The drug candidate is administered orally. It is a dual inhibitor of CYP17 and CYP11B2.

Laekna Therapeutics Shanghai overview

Laekna Therapeutics Shanghai, a biotech company that focused on innovative drug discovery and development. The company is headquartered in China.

Quick View LAE-001 LOA Data

Report Segments
  • Innovator
Drug Name
  • LAE-001
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.